<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Artelo Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/artelo-biosciences-inc</link>
<description>Latest news and press releases for Artelo Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 12:25:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/artelo-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835482678dffbe2df0e3b38.webp</url>
<title>Artelo Biosciences Inc</title>
<link>https://6ix.com/company/artelo-biosciences-inc</link>
</image>
<item>
<title>Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-strategic-collaboration-with-artificial-intelligence-ai-leader-sciencemachine-highlighting-new-expansion-opportunities-and-insights-for-fabp5-inhibitor-development</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-strategic-collaboration-with-artificial-intelligence-ai-leader-sciencemachine-highlighting-new-expansion-opportunities-and-insights-for-fabp5-inhibitor-development</guid>
<pubDate>Tue, 28 Apr 2026 12:25:00 GMT</pubDate>
<description>SOLANA BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced details of a strategic partnership with BioAI company ScienceMachine to accelerate the development of its fatty acid-binding protein 5 (FABP5) inhibitor platform. ScienceMachine’s platform, which</description>
</item>
<item>
<title>Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-announces-peer-reviewed-publication-supporting-its-fabp5-inhibitor-art2612-as-a-novel-pain-treatment-with-a-potentially-first-in-class-profile</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-announces-peer-reviewed-publication-supporting-its-fabp5-inhibitor-art2612-as-a-novel-pain-treatment-with-a-potentially-first-in-class-profile</guid>
<pubDate>Mon, 20 Apr 2026 11:50:00 GMT</pubDate>
<description>Demonstrates ART26.12’s Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multiple Ascending Dose Study This Year Phase 1 SAD Study Exhibited Excellent Safety with Zero Adverse Events Attributed to ART26.12 SOLANA BEACH, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurologic</description>
</item>
<item>
<title>Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-regains-compliance-with-nasdaq-listing-requirements</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-regains-compliance-with-nasdaq-listing-requirements</guid>
<pubDate>Tue, 07 Apr 2026 11:50:00 GMT</pubDate>
<description>Nasdaq confirms Company has regained compliance with Listing Rules 5550(b)(1) and 5620(a)SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced that it has received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has r</description>
</item>
<item>
<title>Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-closing-of-dollar110-million-private-placement-priced-at-the-market-under-nasdaq-rules</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-closing-of-dollar110-million-private-placement-priced-at-the-market-under-nasdaq-rules</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>SOLANA BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced the closing of its previously announced</description>
</item>
<item>
<title>Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-dollar110-million-private-placement-priced-at-the-market-under-nasdaq-rules</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-dollar110-million-private-placement-priced-at-the-market-under-nasdaq-rules</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive</description>
</item>
<item>
<title>Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-expands-art2713-development-as-a-potential-companion-therapy-to-glp-1-treatments</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-expands-art2713-development-as-a-potential-companion-therapy-to-glp-1-treatments</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of</description>
</item>
<item>
<title>Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-announces-third-party-fully-funded-clinical-study-agreement-to-evaluate-art2713-in-glaucoma-patients</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-announces-third-party-fully-funded-clinical-study-agreement-to-evaluate-art2713-in-glaucoma-patients</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmology First patient enrollment</description>
</item>
<item>
<title>Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-provides-business-update-highlighting-clinical-progress-and-reports-fiscal-2025-year-end-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-provides-business-update-highlighting-clinical-progress-and-reports-fiscal-2025-year-end-financial-results</guid>
<pubDate>Tue, 24 Feb 2026 13:00:00 GMT</pubDate>
<description>Positive human data and upcoming clinical catalysts across portfolioSOLANA BEACH, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the fiscal year ended Decemb</description>
</item>
<item>
<title>Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-bioscience-commends-presidential-executive-140000092</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-bioscience-commends-presidential-executive-140000092</guid>
<pubDate>Tue, 23 Dec 2025 14:00:00 GMT</pubDate>
<description>SOLANA BEACH, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today commented on the White House’s recent Executive Order establishing a Medicare pilot program to support reimbursement and structured data collection for cannabidiol (CBD) products.</description>
</item>
<item>
<title>Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-publication-peer-133000549</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-publication-peer-133000549</guid>
<pubDate>Wed, 03 Dec 2025 13:30:00 GMT</pubDate>
<description>Findings further validate FABP5 inhibition and strengthen the therapeutic potential of Artelo’s FABP5 platform for mood and stress-related disordersSOLANA BEACH, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the publication of ne</description>
</item>
<item>
<title>Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclin...</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-publication-of-new-peer-reviewed-study-demonstrating-intraperitoneal-administration-of-a-novel-fatty-acid-binding-protein-5-fabp5-inhibitor-significantly-reduces-stress-induced-anxiety-and-depression-behaviors-in-preclin</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-publication-of-new-peer-reviewed-study-demonstrating-intraperitoneal-administration-of-a-novel-fatty-acid-binding-protein-5-fabp5-inhibitor-significantly-reduces-stress-induced-anxiety-and-depression-behaviors-in-preclin</guid>
<pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
<description>Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5</description>
</item>
<item>
<title>Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-provides-business-reports-130000137</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-provides-business-reports-130000137</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>Encouraging Clinical Progress, Including Positive Interim Phase 2 Results for the Treatment of Cancer Anorexia Cachexia SyndromeSOLANA BEACH, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results fo</description>
</item>
<item>
<title>Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-publication-peer-133000812</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-publication-peer-133000812</guid>
<pubDate>Tue, 04 Nov 2025 13:30:00 GMT</pubDate>
<description>Highlights Broad Development Potential of Proprietary Portfolio Targeting FABPsSOLANA BEACH, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces the publication of a peer-reviewed article, “The Emerging Role of Fatty Acid Binding Protein 3 (FABP3) in Cancers”, in Drug</description>
</item>
<item>
<title>Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-names-veteran-life-sciences-executive-mark-spring-cpa-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-names-veteran-life-sciences-executive-mark-spring-cpa-as-chief-financial-officer</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating</description>
</item>
<item>
<title>Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-expanded-clinical-131500725</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-expanded-clinical-131500725</guid>
<pubDate>Wed, 15 Oct 2025 13:15:00 GMT</pubDate>
<description>ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and Activity Improvements in the Treated Patients versus Placebo SOLANA BEACH, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living w</description>
</item>
<item>
<title>Artelo Biosciences Announces Closing of $2.0 Million Public Offering</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-closing-2-200500298</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-closing-2-200500298</guid>
<pubDate>Wed, 01 Oct 2025 20:05:00 GMT</pubDate>
<description>SOLANA BEACH, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the closing of its previously announced underwritten public offering of 441,210 shares of its common stock at a price to the public of $4.40 per share and pre-funded warrants to purchase up to 13,335</description>
</item>
<item>
<title>Artelo Biosciences Announces Pricing of $2.0 Million Public Offering</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-pricing-2-123000980</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-pricing-2-123000980</guid>
<pubDate>Tue, 30 Sep 2025 12:30:00 GMT</pubDate>
<description>SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of its previously announced underwritten public offering of 441,210 shares of its common stock at a price to the public of $4.40 per share and pre-funded warrants to purchase up to 13,33</description>
</item>
<item>
<title>Artelo Biosciences Announces Proposed Underwritten Public Offering</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-proposed-underwritten-231500467</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-proposed-underwritten-231500467</guid>
<pubDate>Mon, 29 Sep 2025 23:15:00 GMT</pubDate>
<description>SOLANA BEACH, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced it has commenced an underwritten public offering of its common stock and/or pre-funded warrants. All shares of common stock and/or pre-funded warrants in the offering are to be offered by the Compan</description>
</item>
<item>
<title>Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-presentation-positive-123000357</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-presentation-positive-123000357</guid>
<pubDate>Mon, 29 Sep 2025 12:30:00 GMT</pubDate>
<description>Patients treated with ART27.13 showed consistent improvements in weight, lean body mass, and activity While clinical benefits were observed in all treated cohorts, the best outcomes in CAReS were observed in patients titrated to the highest dose SOLANA BEACH, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatolog</description>
</item>
<item>
<title>Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms</title>
<link>https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-publication-preclinical-123000179</link>
<guid isPermaLink="true">https://6ix.com/company/artelo-biosciences-inc/news/artelo-biosciences-announces-publication-preclinical-123000179</guid>
<pubDate>Wed, 10 Sep 2025 12:30:00 GMT</pubDate>
<description>SOLANA BEACH, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the publication of new preclinical data on ART12.11, its proprietary cannabidiol:tetramethylpyrazine (CBD:TMP) cocrystal. The peer-reviewed study, conducted in collaboration with researchers at West</description>
</item>
</channel>
</rss>